Short Interest in Actuate Therapeutics, Inc. (NASDAQ:ACTU) Drops By 40.4%

Actuate Therapeutics, Inc. (NASDAQ:ACTU) was the recipient of a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 450,180 shares, a decrease of 40.4% from the July 15th total of 754,754 shares. Based on an average daily volume of 155,092 shares, the days-to-cover ratio is currently 2.9 days. Approximately 4.5% of the company’s shares are sold short.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on ACTU shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 24th. HC Wainwright reissued a “buy” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 10th. Wall Street Zen downgraded shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Finally, Rodman & Renshaw assumed coverage on shares of Actuate Therapeutics in a research report on Thursday, July 30th. They set a “buy” rating and a $6.00 price target on the stock. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $13.67.

Institutional Investors Weigh In On Actuate Therapeutics

Several large investors have recently bought and sold shares of ACTU. Voss Capital LP boosted its stake in shares of Actuate Therapeutics by 45.0% in the 4th quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock valued at $7,956,000 after buying an additional 403,722 shares during the period. Vanguard Group Inc. grew its holdings in Actuate Therapeutics by 19.5% during the 3rd quarter. Vanguard Group Inc. now owns 316,010 shares of the company’s stock worth $2,114,000 after acquiring an additional 51,546 shares in the last quarter. Geode Capital Management LLC grew its holdings in Actuate Therapeutics by 42.9% during the 4th quarter. Geode Capital Management LLC now owns 207,744 shares of the company’s stock worth $1,271,000 after acquiring an additional 62,332 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Actuate Therapeutics in the 2nd quarter valued at approximately $157,000. Finally, BlackRock Inc. acquired a new stake in shares of Actuate Therapeutics in the 2nd quarter valued at $138,000.

Actuate Therapeutics Stock Performance

NASDAQ ACTU opened at $1.01 on Monday. The stock has a market cap of $24.17 million, a PE ratio of -1.16 and a beta of 0.78. Actuate Therapeutics has a twelve month low of $0.90 and a twelve month high of $9.22. The stock has a fifty day simple moving average of $1.49 and a 200-day simple moving average of $2.47.

Actuate Therapeutics (NASDAQ:ACTU) last posted its earnings results on Friday, August 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.01. Research analysts predict that Actuate Therapeutics will post -0.86 EPS for the current year.

Actuate Therapeutics Company Profile

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.